Blueclinical Investigacao E Desenvolvimento Em Saude Lda.
Verified
Porto, Portugal
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This study aims to compare how much of a medication enters the bloodstream when using two different versions of the same drug. The research focuses on empagliflozin, which is provided in two forms: a test version and the brand-name version known as Jardiance. Both are administered as a 25 mg film-coated tablet, which is a pill covered in a thin layer to make it easier to swallow.
The study examines bioavailability, a term used to describe the rate and amount at which a drug is absorbed by the body and becomes available at the site of action. This research will be conducted in healthy individuals under fasting conditions, meaning participants will not eat before taking the medication. Participants will undergo a crossover process, where they receive both types of tablets at different times during the study to allow for a direct comparison between the two products.
The trial runs in 3 steps – from screening to follow-up. Each step says what happens and what the team monitors.
11 criteria
28 criteria
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Porto, Portugal
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
is a medication used to help manage blood sugar levels. In this study, it is being tested to see how well the body absorbs the medicine when taken as a tablet.
is a medication used to help manage blood sugar levels. In this study, it is being used as a comparison to see how its absorption in the body compares to the test medication.
This medication is taken orally in the form of a film-coated tablet. It is an established medicine used primarily to manage type 2 diabetes and to help protect the heart and kidneys. It belongs to a group of drugs called SGLT2 inhibitors, which work by preventing the kidneys from reabsorbing sugar back into the blood, allowing the excess sugar to be removed from the body through urine.
This medication is taken orally in the form of a film-coated tablet. It is an established medicine used primarily to manage type 2 diabetes and to help protect the heart and kidneys. It belongs to a group of drugs called SGLT2 inhibitors, which work by preventing the kidneys from reabsorbing sugar back into the blood, allowing the excess sugar to be removed from the body through urine.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.